MétaCan
Menu
Back to cohort
Record W4407976789 · doi:10.1016/j.jtct.2025.01.176

Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia

2025· article· en· W4407976789 on OpenAlexaff
Rasha W Al-Ali, Gege Gui, Niveditha Ravindra, Georgia Andrew, Devdeep Mukherjee, Zoë C. Wong, Ying Huang, Jason Gerhold, Matt Holman, Austin Jacobsen, J. D'Angelo, Jeffrey E. Miller, Karina Elias, Jeffery J. Auletta, Firas El Chaer, Steven M. Devine, Antonio Jiménez, Marcos de Lima, Mark R. Litzow, Partow Kebriaei, Wael Saber, Stephen R. Spellman, Scott L. Zeger, Kristin Page, Coleman Lindsley, Jerald P. Radich, Laura W. Dillon, Christopher S. Hourigan

Bibliographic record

VenueTransplantation and Cellular Therapy · 2025
Typearticle
Languageen
FieldMedicine
TopicAcute Myeloid Leukemia Research
Canadian institutionsInstitute of Cancer Research
Fundersnot available
KeywordsNPM1Myeloid leukemiaMinimal residual diseaseMedicineResidualCancer researchLeukemiaOncologyImmunologyBiologyGeneticsComputer scienceGeneKaryotype

Abstract

fetched live from OpenAlex

Introduction NPM1 mutations, seen in ∼30% of adult acute myeloid leukemia (AML) cases, often co-occur with FLT3 internal tandem duplication ( FLT3 -ITD). Measurable residual disease (MRD) testing before allogeneic hematopoietic cell transplant (alloHCT) for persistence of mutated NPM1 or FLT3 -ITD in AML patients in complete remission (CR) can identify those at highest risk of relapse and death. Quantitative RT-PCR assays are currently recommended for NPM1 MRD testing, while FLT3 -ITD is DNA-based next generation sequencing (NGS). Objectives DNA-based NGS assays for NPM1 MRD testing may have several advantages but require validation. This study aimed to evaluate these assays in blood from patients with AML in CR1 before alloHCT. Methods 190 of 531 patients from the Pre-MEASURE study (PMID: 36881031), aged ³18, with NPM1 -mutated AML who underwent alloHCT in CR1 at a CIBMTR reporting site in the USA between 2013-2019, were randomly selected for MRD testing using a commercially available NGS assay (Invivoscribe, San Diego, CA), validated to detect NPM1 MRD down to a variant allele fraction (VAF) of 0.005%. The results were compared with an anchored multiplex PCR-based (AMP) targeted NGS assay and, where available, FLT3 -ITD MRD results. Results NPM1 NGS MRD testing was successful in 186/190 patients, detecting NPM1 insertion variants in 71 (38%) patients with a median VAF of 0.003% (range: 0.0002-2.1%). The presence of NPM1 MRD pre-alloHCT was associated with significantly increased rate of relapse (40% vs 15% at 3 years; HR=3.4; P<0.001) and decreased overall survival (OS) (50% vs 75% at 3 years; HR=2.9; P<0.001). In multivariable analysis, residual NPM1 MRD burden pre-alloHCT was associated with risk of relapse and mortality in a dose-dependent manner ( Figure 1 ). 123 (66%) patients were co-mutated for FLT3 -ITD at baseline and had undergone prior testing for FLT3 -ITD MRD (PMID: 38696205). When MRD was defined by the presence of NPM1 alone vs NPM1 and/or FLT3 -ITD, relapse and OS at 3 years were similar ( Figure 2 ). These findings were confirmed in the full Pre-MEASURE cohort (n=317) using the AMP assay. NPM1 MRD positive patients who received nonmyeloablative or reduced-intensity conditioning (RIC) without melphalan (mel) had increased risk of relapse or mortality compared to patients who received myeloablative conditioning or RIC with mel, independent of FLT3 -ITD co-mutational status ( Figure 3). Conclusions In patients with NPM1 -mutated AML, the detection of residual NPM1 variants in pre-alloHCT blood during CR1 using a highly sensitive DNA-based assay is associated in a dose-dependent manner with a significantly increased risk of relapse and mortality post-alloHCT. This risk can be partly mitigated by conditioning regimen. For patients with both NPM1 and FLT3 -ITD mutations at diagnosis, NPM1 should be prioritized as the primary target for MRD assessment if only one test is feasible.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.006

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.019
GPT teacher head0.295
Teacher spread0.276 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractno

Explore more

Same venueTransplantation and Cellular TherapySame topicAcute Myeloid Leukemia ResearchFrench-language works237,207